BEST SELLING CANCER DRUGS | 2024
BRAND | REVENUES | |
1 | Keytruda | $6.9 billion |
2 | Darzalex | $2.7 billion |
3 | Opdivo | $2.1 billion |
4 | Revlimid | $1.7 billion |
5 | Imbruvica | $1.6 billion |
6 | Tagrisso | $1.6 billion |
7 | Imfinzi | $1.1 billion |
8 | Ibrance | $1.0 billion |
9 | Verzenios | $1.0 billion |
10 | Tecentriq | $1.0 billion |
1. Keytruda (Pembrolizumab)
Company: Merck & Co.
Mechanism of Action: Keytruda is an immune checkpoint inhibitor that targets the programmed cell death protein 1 (PD-1). By blocking PD-1, it enhances the immune system’s ability to recognize and attack cancer cells.
Indications: Keytruda is approved for various cancers, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and more.
The Merck Access Program for Keytruda provides valuable resources and support for healthcare professionals and their patients.
Coverage Assistance: The program helps determine coverage for patients by offering information about the Merck Co-pay Assistance Program and the Merck Patient Assistance Program. It can assist with benefit investigations, billing and coding, co-pay assistance for eligible patients, prior authorizations, appeals processes, and referrals to the Merck Patient Assistance Program for eligibility determination1.
Co-pay Assistance: Privately insured patients who need help affording the out-of-pocket costs for KEYTRUDA can benefit from the Merck Co-pay Assistance Program. Eligible patients pay only the first $25 of their co-pay per infusion, with a maximum benefit of $25,000 per patient during each eligibility period2.
Reimbursement and Insurance Coverage: The Merck Access Program provides reimbursement and insurance coverage-related information throughout the patient’s treatment process
2. Darzalex (Daratumumab)
Company: Johnson & Johnson
Mechanism of Action: Darzalex is a monoclonal antibody that targets CD38 on the surface of myeloma cells. It induces cell death and enhances the immune system’s response against cancer.
Indications: Darzalex is primarily used for multiple myeloma.
Successful Factors: Its efficacy, especially in relapsed/refractory myeloma, and ongoing clinical trials contribute to its popularity.
3. Opdivo (Nivolumab)
Company: Bristol Myers Squibb
Mechanism of Action: Opdivo is another PD-1 inhibitor, similar to Keytruda. It unleashes the immune system to fight cancer cells.
Indications: Opdivo is approved for various cancers, including melanoma, lung cancer, renal cell carcinoma, and more.
Successful Factors: Opdivo’s broad indications, durable responses, and combination therapies make it a top choice1.
4. Revlimid (Lenalidomide)
Company: Bristol Myers Squibb
Mechanism of Action: Revlimid modulates the immune system and has anti-angiogenic properties. It is used primarily for multiple myeloma and myelodysplastic syndromes.
Indications: Multiple myeloma, mantle cell lymphoma, and myelodysplastic syndromes.
Successful Factors: Revlimid’s efficacy, oral administration, and ongoing research contribute to its sales1.
5. Imbruvica (Ibrutinib)
Company: Johnson & Johnson (in partnership with AbbVie)
Mechanism of Action: Imbruvica inhibits Bruton’s tyrosine kinase (BTK), disrupting B-cell signaling pathways. It is effective against B-cell malignancies.
Indications: Chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenström macroglobulinemia.
Successful Factors: Imbruvica’s targeted therapy and clinical evidence drive its sales.
6. Tagrisso (Osimertinib)
Company: AstraZeneca
Mechanism of Action: Tagrisso is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It targets EGFR mutations in non-small cell lung cancer.
Indications: Non-small cell lung cancer with EGFR T790M mutations.
Successful Factors: Tagrisso’s specificity for EGFR mutations and improved survival rates contribute to its popularity.
7. Imfinzi (Durvalumab)
Company: AstraZeneca
Mechanism of Action: Imfinzi is another PD-1/PD-L1 inhibitor. It enhances the immune response against cancer cells.
Indications: Non-small cell lung cancer, bladder cancer, and other solid tumors.
Successful Factors: Imfinzi’s role in immunotherapy and ongoing clinical trials drive its sales.
8. Ibrance (Palbociclib)
Company: Pfizer
Mechanism of Action: Ibrance inhibits cyclin-dependent kinases (CDKs), specifically CDK4 and CDK6. It is used in breast cancer.
Indications: Metastatic breast cancer.
Successful Factors: Ibrance’s targeted approach and combination therapies contribute to its market share.
9. Verzenios (Abemaciclib)
Company: Eli Lilly
Mechanism of Action: Verzenios also inhibits CDK4 and CDK6. It is used in breast cancer.
Indications: Breast cancer
10. Tecentriq (Atezolizumab)
Company: Roche/Genentech
Mechanism of Action: Tecentriq is a PD-L1 inhibitor, similar to Keytruda and Opdivo. It blocks the interaction between PD-L1 and PD-1, allowing the immune system to attack cancer cells.
Indications: Tecentriq is used in various cancers, including bladder cancer, non-small cell lung cancer, and triple-negative breast cancer.
Successful Factors: Tecentriq’s efficacy in specific cancer types and ongoing research contribute to its sales.
Comments